101 related articles for article (PubMed ID: 23268013)
41. Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer.
Liu ZP; Li LM; Liu XL; Zhang DX
Onkologie; 2012; 35(3):108-13. PubMed ID: 22414974
[TBL] [Abstract][Full Text] [Related]
42. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
43. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
44. The miniscule benefit of serial carcinoembryonic antigen monitoring after effective curative treatment for primary colorectal cancer.
Wolf RF; Cohen AM
J Am Coll Surg; 1997 Jul; 185(1):60-4. PubMed ID: 9208962
[TBL] [Abstract][Full Text] [Related]
45. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer.
Japink D; Leers MP; Sosef MN; Nap M
Anticancer Res; 2009 Aug; 29(8):3245-51. PubMed ID: 19661342
[TBL] [Abstract][Full Text] [Related]
46. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
47. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of serum P53 antibody in patients with gastric cancer.
Shiota G; Ishida M; Noguchi N; Takano Y; Oyama K; Okubo M; Katayama S; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Ito H; Kawasaki H
Res Commun Mol Pathol Pharmacol; 1998 Jan; 99(1):41-51. PubMed ID: 9523354
[TBL] [Abstract][Full Text] [Related]
49. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
[TBL] [Abstract][Full Text] [Related]
50. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer.
Iinuma H; Okinaga K; Egami H; Mimori K; Hayashi N; Nishida K; Adachi M; Mori M; Sasako M
Int J Oncol; 2006 Feb; 28(2):297-306. PubMed ID: 16391782
[TBL] [Abstract][Full Text] [Related]
51. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters.
Wu J; Qiu T; Pan P; Yu D; Ju Z; Qu X; Gao X; Mao C; Wang L
Asian Pac J Cancer Prev; 2011; 12(11):2921-4. PubMed ID: 22393964
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Ootani K; Yasuda K; Murono K; Watanabe T
Oncology; 2017; 92(1):31-38. PubMed ID: 27794579
[TBL] [Abstract][Full Text] [Related]
53. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
54. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Locker GY; Hamilton S; Harris J; Jessup JM; Kemeny N; Macdonald JS; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2006 Nov; 24(33):5313-27. PubMed ID: 17060676
[TBL] [Abstract][Full Text] [Related]
55. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma.
Takahashi K; Miyashita M; Nomura T; Makino H; Futami R; Kashiwabara M; Katsuta M; Tajiri T
Dis Esophagus; 2007; 20(2):117-22. PubMed ID: 17439594
[TBL] [Abstract][Full Text] [Related]
56. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
57. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
58. Significance of Serum p53 Antibody as a Tumor Marker in Colorectal Cancer.
Takahashi R; Sakamoto K; Sugimoto K; Motegi S; Tsukamoto R; Ichikawa R; Okazawa Y; Aoki J; Ishiyama S; Takahashi M; Kojima Y; Okuzawa A; Tomiki Y; Matsuoka J
Dis Markers; 2019; 2019():2721876. PubMed ID: 31929839
[TBL] [Abstract][Full Text] [Related]
59. Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.
Yamaguchi T; Takii Y; Maruyama S
Surg Today; 2014 Aug; 44(8):1529-35. PubMed ID: 23975589
[TBL] [Abstract][Full Text] [Related]
60. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
Shimizu K; Ueda Y; Yamagishi H
Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
